# US 2014/0155371 A1 · Multicomponent crystalline system of ezetimibe and proline

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155371 A1
- Document ID: US20140155371A1
- Status: Published application
- Kind: A1
- Application number: 14/234,158
- Filed: 2012-07-24
- Published: 2014-06-05
- Earliest claimed: 2011-07-26
- Assignees: BASF SE
- Inventors: Andreas Hafner; Tobias Hintermann; Martin Szelagiewicz; Bernd Siebenhaar; Fritz Blatter
- Web page: https://patentgrep.com/patent/US20140155371A1

## CPC

- C07D 205/08: with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07B 57/00: Separation of optically-active compounds
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Provided is a crystalline composition comprising a mixture of a compound of formula 1 (Ezetimibe) and proline or proline derivatives, or a hydrate/solvate thereof, as well as a process for obtaining the same. And a process for the purification of Ezetimibe is also disclosed.

## Claims

### Claim 1

A composition, comprising:
a compound of formula 1:
and
proline, or a proline derivative.

### Claim 2 (depends on 1)

The composition according to claim 1 which is a crystalline composition comprising a mixture of
the compound of formula 1:
and
the proline or the proline derivative.

### Claim 3 (depends on 1)

The composition according claim 1 which forms a single crystalline phase (co-crystal).

### Claim 4 (depends on 1)

The composition of claim 1, comprising the compound of formula 1 and proline, or a hydrate/solvate of said composition.

### Claim 5 (depends on 1)

The composition of claim 1, wherein a molar ratio of the compound of formula 1 and the proline or the proline derivative is the range of from 1:0.5 to 1:2.1.

### Claim 6 (depends on 1)

The composition of claim 1, having an XRPD pattern with characteristic peaks (expressed in 2θ±0.2°2θ; CuKα radiation) at 16.3, 17.0, 19.0, 20.0, 22.4, and 24.5°.

### Claim 7 (depends on 6)

The composition according to claim 6, having an XRPD pattern with characteristic peaks (expressed in 2θ±0.2°2θ; CuKα radiation) at 9.5, 12.9, 16.3, 16.7, 17.0, 19.0, 20.0, 22.4, 24.5, and 25.3°.

### Claim 8 (depends on 1)

The composition of claim 1, comprising the compound of formula 1 and (S)-proline, said composition being a co-crystal wherein a molar ratio of the compound of formula 1 and the (S)-proline is in the range of from 1:0.9 to 1:1.1.

### Claim 9 (depends on 2)

A process for obtaining the composition of claim 2, the process comprising:
a) combining the compound of formula 1, or a mixture comprising the compound of the formula 1:
with a solvent or a mixture of solvents, to form a mixture a);
b) adding the proline or the proline derivative to the mixture a) to obtain a composition b);
c) optionally concentrating the composition b) and/or adding an antisolvent;
d) crystallizing to form a suspension d);
e) optionally equilibrating the suspension d); and
f) isolating a precipitate formed from the step d) and/or the step e).

### Claim 10 (depends on 1)

A process for purifying the compound of formula 1:
the process comprising:
combining the composition of claim 1 with a solvent, to form a solution or dispersion; and
isolating the composition as a crystalline composition.

### Claim 11 (depends on 9)

The process according to claim 9, wherein a molar ratio of the compound of formula 1 and the proline or the proline derivative is in the range from 1:0.5 to 1:3.

### Claim 12 (depends on 9)

The process of claim 9, wherein proline is added in the step b).

### Claim 13 (depends on 9)

The process of claim 9, wherein the solvent or the mixture of solvents is selected from the group consisting of a C1-C4 alcohol, a C3-C6 ketone, an ether, a C1-C4 alkylester, acetonitrile, a hydrocarbon, and a mixture thereof.

### Claim 14 (depends on 9)

The process of claim 9, further comprising adding seed crystals.

### Claim 15 (depends on 2)

A pharmaceutical composition, comprising the composition of claim 2 and optionally one or more pharmaceutically acceptable excipients.

### Claim 16 (depends on 15)

The pharmaceutical composition according to claim 15, which is a solid having at least one characteristic peak in an x-ray powder diffractogram (expressed in 2θ±0.2°2θ (CuKα radiation)) selected from the group consisting of 12.9, 16.3, 17.0, 19.0, 20.0, 22.4, and 24.5°.

### Claim 17 (depends on 1)

The composition of claim 1, comprising at least one proline derivative selected from the group consisting of 2-methylproline, 3-methylproline, 4-methylproline, 5-methylproline, N-methylproline, proline methylester, 4-hydroxyproline, and 3,4-dehydroproline.

### Claim 18 (depends on 1)

The composition of claim 1, comprising at least one proline derivative selected from the group consisting of (S)-proline, 2-methyl-(S)-proline, 3-methyl-(S)-proline, 4-methyl-(S)-proline, 5-methyl-(S)-proline, N-methyl-(S)-proline, (S)-proline methylester, 4-hydroxy-(S)-proline, and 3,4-dehydro-(S)-proline.

### Claim 19 (depends on 2)

The composition of claim 2, comprising a proline derivative selected from the group consisting of 2-methylproline, 3-methylproline, 4-methylproline, 5-methylproline, N-methylproline, proline methylester, 4-hydroxyproline, and 3,4-dehydroproline.
